Endocrine Abstracts

Patients with small bowel NET may present in a different way from other GPNET patients, with well-established disease and metastases. They may have long term symptoms that are well investigated but remain undiagnosed sometimes for years. To examine this supposition the presenting symptoms and outcomes of the first thirty patients with small bowel NET seen in 2018 were examined. Of these thirty patients eight were female and twenty-two were male with a median age of 64.5 years ...

Introduction: Bile acid malabsorption (BAM) may be a contributing factor causing diarrhoea in patients with NETs, particularly among those who have undergone previous surgical resection of the terminal ileum and/or right colon or cholecystectomy (Naraev et al 2019). Aim(s): To identify the prevalence of bile acid malabsorption in neuroendocrine tumour patients (NET) at the Queen Elizabeth Hospital Birmingham (QEHB). Materi...

Background: The Birmingham Neuroendocrine Tumour (NET) service has a full time dedicated NET Dietitian for outpatient and inpatient care since August 2020. An anonymised survey of patient experience was performed to identify ways in which we can improve the service for patients. 87 potential patients were identified. 8 had passed away. 79 questionnaires were sent out. 38 were returned via a self-addressed envelope.Results: • 53% of patients were fir...

Introduction: Duodenal neuro endocrine tumors (d-NETs) comprise about 2% of all NETs. Treatment of d-NETs involves resection of the tumour either by endoscopic or surgical resection. Local resection of the lesion is usually a safer option compared to a more radical pancreaticoduodenectomy. However, inadequate clearance by local resection might result in recurrent disease and reduce the overall survival. There is no current available evidence regarding the extent of resection.<...

Somatostatin analogues (SSAs) are regularly used in the treatment of neuroendocrine tumours (NETs) to control the symptoms of hormonal hypersecretion. Evidence shows that SSAs can reduce tumour progression, and are therefore also being used in patients with non-functioning tumours. As many NETs present with advanced disease curative therapy is often not possible; therefore, assessing the impact of therapy on quality of life (QoL) is vital to patient management. This is particu...

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is documented as a pre-malignant condition by the World Health Organisation. Patients with pulmonary nodules typically undergo 5′-18fluoro-deoxy-D-glucose (FDG) positron emission tomography combined with computed tomography (PETCT) for further diagnostic investigation. DIPENCH is widely accepted as an FDG negative pathology. The purpose of this analysis was to a...

Severe tricuspid regurgitation (TR) leads to a reduction in cardiac output and an increase in the central venous pressure, resulting in secondary organ dysfunction. Surgery for severe TR is a high-risk procedure, particularly in the presence of uncontrolled carcinoid syndrome (CS) symptoms. Replacement of leaking tricuspid valves can lead to reduction in tumour markers and improvement in carcinoid symptoms. Transcatheter valve implantation into the vena cava may be an alternat...

The treatment of patients with carcinoid heart disease (CHD) presents substantial challenges due to the advanced multisystem nature of their disease. Intensive multidisciplinary collaboration and innovative techniques are often required in order to manage these patients. Here we describe two such cases from our institution. A 59-year old gentleman with metastatic NET and CHD was referred to our centre. Transoesophageal echocardiography demonstrated severe tricuspid regurgitati...

Background: CALM-NET (EudraCT 2013-002194-22; NCT02075606), a prospective, exploratory study, evaluated enumeration of pre-treatment circulating tumour cells as a predictor of symptomatic response to lanreotide autogel (LAN) in patients with functional midgut neuroendocrine tumours (NETs). Here, we describe the effect of LAN on biomarkers.Methods: Patients, ≥18 years, with functional, well- or moderately-differentiated midgut NETs were treated with...

Long acting somatostatin analogues (SSA) such as Sandostatin LAR and Lanreotide Autogel are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.Methods:...